Global Alpha Capital Management Ltd. Has $34.53 Million Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Global Alpha Capital Management Ltd. increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 624,550 shares of the specialty pharmaceutical company's stock after purchasing an additional 88,100 shares during the period. ANI Pharmaceuticals makes up 2.5% of Global Alpha Capital Management Ltd.'s holdings, making the stock its 16th biggest holding. Global Alpha Capital Management Ltd. owned 2.97% of ANI Pharmaceuticals worth $34,525,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. US Bancorp DE increased its holdings in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the period. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after acquiring an additional 579 shares during the last quarter. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the third quarter worth $222,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

ANIP has been the topic of several research analyst reports. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $85.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Up 3.0 %

ANIP traded up $1.86 during trading on Wednesday, reaching $63.26. 870,783 shares of the stock traded hands, compared to its average volume of 243,091. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock's 50-day moving average is $57.98 and its 200 day moving average is $58.07. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The stock has a market capitalization of $1.38 billion, a PE ratio of -115.02 and a beta of 0.62.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,300 shares of company stock worth $584,869. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.